Advertisement

Topics

Radial Artery Clamp Times in Patients Undergoing Cardiac Catheterization Via Transradial Approach

2015-03-17 02:54:20 | BioPortfolio

Published on BioPortfolio: 2015-03-17T02:54:20-0400

Clinical Trials [3103 Associated Clinical Trials listed on BioPortfolio]

Patient Comfort With Vascular Closure

The purpose of this research study is to collect information on the amount of discomfort patients experience with one of two different vascular blood vessel closure devices, the MynxM5 Vas...

Optimized Heparin Regimen in Vascular Surgery

Hypothesis: Optimal anticoagulation defined as an Activated Clotting Time (ACT) of 300 to 350 seconds obtained by weight-adjusted doses of unfractionated heparin (UFH) will improve the hem...

Safety and Efficacy of Using HDH Device and Method - a Novel Sutureless Vascular Anastomosis

The HDH device is intended for creating sutureless vascular anastomosis in various blood vessels. The HDH device consists of four parts: an elastic tube (graft), docking head (anastomotic ...

Rapid Clamp Release Post Trans-radial Cardiac Catheterization

The purpose of the study is to compare different short durations of radial clamp application following an angiogram via a trans-radial approach.

A Feasibility Study Evaluating the Use of SafeBreak Vascular in the Geriatric Trauma Population

SafeBreak Vascular is a medical device indicated for fluid flow control during the administration of IV fluids/medication to the patient's vascular system and to aid in the prevention of u...

PubMed Articles [17683 Associated PubMed Articles listed on BioPortfolio]

Anticoagulation Obtained Below the Arterial Clamp Using a Single Fixed Bolus of Heparin in Vascular Surgery: A Pilot Study.

No clear recommendations exist regarding the optimal dosing of unfractionated heparin (UFH) during vascular surgery. Moreover, little is known about the effect of the UFH bolus downstream of the arter...

Implementation of the EXOSEAL Vascular Closure Device in the Transpopliteal Arterial Approach.

To investigate the feasibility and safety of the EXOSEAL vascular closure device (VCD) in achieving hemostasis in transpopliteal arterial interventions.

Hypoxia Signaling in Vascular Homeostasis.

Hypoxia signaling in the vasculature controls vascular permeability, inflammation, vascular growth, and repair of vascular injury. In this review, we summarize recent insights in this burgeoning field...

Vascular Anomalies (Part II): Interventional Therapy of Peripheral Vascular Malformations.

 The International Society for the Study of Vascular Anomalies (ISSVA) categorizes vascular anomalies into vascular tumors and vascular malformations. Vascular malformations are further divided into...

Pediatric Vascular Surgical Practice Patterns.

Vascular surgeons infrequently care for pediatric patients. As such, variability in operative management and available hospital resources at free-standing children's hospitals may exist. The study aim...

Medical and Biotech [MESH] Definitions

The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.

Secondary headache disorders attributed to a variety of cranial or cervical vascular disorders, such as BRAIN ISCHEMIA; INTRACRANIAL HEMORRHAGES; and CENTRAL NERVOUS SYSTEM VASCULAR MALFORMATIONS.

A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR C in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.

A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR D in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.

The active alterations of vascular wall structures, often leading to elevated VASCULAR RESISTANCE. It is associated with AGING; ATHEROSCLEROSIS; DIABETES MELLITUS; HYPERTENSION; PREGNANCY; PULMONARY HYPERTENSION; and STROKE, but is also a normal part of EMBRYOGENESIS.

More From BioPortfolio on "Radial Artery Clamp Times in Patients Undergoing Cardiac Catheterization Via Transradial Approach"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial